Literature DB >> 8635208

Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression.

M Iwase1, S P Bishop, M Uechi, D E Vatner, R P Shannon, R K Kudej, D C Wight, T E Wagner, Y Ishikawa, C J Homcy, S F Vatner.   

Abstract

To study the physiological effect of the overexpression of myocardial Gsalpha (protein levels increased by approximately threefold in transgenic mice), we examined the responsiveness to sympathomimetic amines by echocardiography (9 MHz) in five transgenic mice and five control mice (both 10.3 +/- 0.2 months old). Myocardial contractility in transgenic mice, as assessed by left ventricular (LV) fractional shortening (LVFS) and LV ejection fraction (LVEF) was not different from that of control mice at baseline (LVFS, 40 +/- 3% versus 36 +/- 2%; LVEF, 78 +/- 3% versus 74 +/- 3%). LVFS and LVEF values in transgenic mice during isoproterenol (ISO, 0.02 micrograms/kg per minute) infusion were higher than the values in control mice (LVFS, 68 +/- 4% versus 48 +/- 3%; LVEF, 96 +/- 1% versus 86 +/- 3%; P < .05). Norepinephrine (NE, 0.2 micrograms/kg per minute) infusion also increased LVFS and LVEF in transgenic mice more than in control mice (LVFS, 59 +/- 4% versus 47 +/- 3%; LVEF, 93 +/- 2% versus 85 +/- 3%; P < .05). Heart rates of transgenic mice were higher than those of control mice during ISO and NE infusion. In three transgenic mice with heart rates held constant, LV dP/dt rose by 33 +/- 2% with ISO (0.02 micrograms/kg per minute) and by only 13 +/- 2% in three wild-type control mice (P < .01). NE (0.1 micrograms/kg per minute) also induced a greater effect on LV dP/dt in the three transgenic mice with heart rates held constant compared with three wild-type control mice (65 +/ 8% versus 28 +/- 4%, P < .05). Pathological and histological analyses of older transgenic mouse hearts (16.0 +/- 0.8 months old) revealed hypertrophy, degeneration, atrophy of cells, and replacement fibrosis reflected by significant increases in collagen volume in the subendocardium (5.2 +/- 1.4% versus 1.2 +/- 0.3%, P < .05) and in the cross-sectional area of myocytes (298 +/- 29 versus 187 +/- 12 micron2, P < .05) compared with control mouse hearts. These results suggest that Gsalpha overexpression enhances the efficacy of the beta-adrenergic receptor-Gs-adenylyl cyclase signaling pathway. This in turn leads to augmented inotropic and chronotropic responses to endogenous sympathetic stimulation. This action over the life of the animal results in myocardial damage characterized by cellular degeneration, necrosis, and replacement fibrosis, with the remaining cells undergoing compensatory hypertrophy. As a model, this transgenic mouse offers new insights into the mechanisms of cardiomyopathy and heart failure and provides a new tool for their study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635208     DOI: 10.1161/01.res.78.4.517

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  54 in total

Review 1.  Molecular and cellular mechanisms of myocardial remodeling.

Authors:  Melanie Maytin; Wilson S Colucci
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

Review 2.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

3.  GNAS gene variants affect β-blocker-related survival after coronary artery bypass grafting.

Authors:  Ulrich H Frey; Jochen D Muehlschlegel; Jürgen Peters; Simon Body; Christoph Ochterbeck; Amanda A Fox; Stanton K Shernan; Charles D Collard; Peter Lichtner
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

Review 4.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 5.  G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function.

Authors:  Douglas G Tilley
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

Review 6.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

7.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

8.  Cardiac dysfunction in aging conscious rats: altered cardiac cytoskeletal proteins as a potential mechanism.

Authors:  Samuel C Lieber; Hongyu Qiu; Li Chen; You-Tang Shen; Chull Hong; William C Hunter; Nadine Aubry; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

Review 9.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

10.  Neonatal organophosphorus pesticide exposure alters the developmental trajectory of cell-signaling cascades controlling metabolism: differential effects of diazinon and parathion.

Authors:  Abayomi A Adigun; Nicola Wrench; Frederic J Seidler; Theodore A Slotkin
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.